Press Release

Read more about the article Pepper Bio Partners with Stanford’s Felsher Lab to Identify Therapy Targets for Untreatable, MYC Addicted Lymphatic and Liver Cancers
Press Release

Pepper Bio Partners with Stanford’s Felsher Lab to Identify Therapy Targets for Untreatable, MYC Addicted Lymphatic and Liver Cancers

Leveraging Pepper Bio’s transomics platform, Dean Felsher’s research team will translate academic findings for the development of more efficacious therapies for lymphoma and hepatocellular carcinoma Today, Pepper Bio, the world’s first transomics drug discovery company, announced a collaboration with the Dean Felsher Laboratory at Stanford University. Leveraging Pepper Bio’s unique platform on phosphoproteomics, the two teams aim to identify and validate novel targets for hepatocellular carcinoma and lymphoma within the year. Read on…

Comments Off on Pepper Bio Partners with Stanford’s Felsher Lab to Identify Therapy Targets for Untreatable, MYC Addicted Lymphatic and Liver Cancers
March 3, 2022
Read more about the article Pepper Bio Emerges from Stealth with ‘Waze for Drug Discovery’ Technology
Pepper Bio's partnership with Stanford's Dean Felsher will target Myc addicted cancers.
Press Release

Pepper Bio Emerges from Stealth with ‘Waze for Drug Discovery’ Technology

Harvard, MIT, Cambridge, Brown & Northwestern Universities trained team leverages proprietary transomics translation technology to open a new era of drug discovery, rediscovery, and rescue. Pepper Bio, the world’s first transomics drug discovery company, emerges from stealth today to leverage its proprietary transomics -- including phosphoproteomics -- data translation technology to discover new drugs, rediscover new uses for existing therapeutics, and rescue drugs that may be on a course toward…

Comments Off on Pepper Bio Emerges from Stealth with ‘Waze for Drug Discovery’ Technology
October 15, 2021